Finding the right dose of EXS73565 for relapsed B-cell cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new oral medication (EXS73565) for people with B-cell blood cancers that came back or didn't respond to standard treatments. It aims to find the best dose and check if it's safe and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You can take care of yourself and are up and around most of the day.
- You have one of these B-cell blood cancers: CLL (including Richter's transformation), mantle cell lymphoma, DLBCL, follicular lymphoma, marginal zone lymphoma, or Waldenström macroglobulinemia.
- You have already tried standard treatments and they didn't work, or your cancer came back.
- You have not had another cancer in the last 5 years (except treated skin cancers).
- You have not had chemotherapy or other cancer treatments in the last 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
This early-stage study tests a new medicine (BGB-16673) that targets B-cell cancer cells in people with specific lymphoma or related blood cancers. It aims to see how well the drug can control the cancer and what side effects it causes, especially in Chinese participants.
This Phase 1 trial tests AC676, a study medicine, for adults with certain B-cell blood cancers that have come back or did not respond to prior treatment. It may help people who have tried standard therapies and need new options.
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
This is an early-stage study testing a new cancer drug called EXS74539 to find the right dose and see how well it works in people with various advanced solid tumors. The drug may help patients whose cancers have stopped responding to standard treatments.
Hear when a new Relapsed or Refractory B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.